A Cohort study of STMN1 expression in colorectal cancer: Body mass index and prognosis

American Journal of Gastroenterology

Volumn 104, Issue 8, 2009, Pages 2047-2056

  Ogino, Shuji ^a,b,c   Nosho, Katsuhiko ^a   Baba, Yoshifumi ^a   Kure, Shoko ^a   Shima, Kaori ^a   Irahara, Natsumi ^a   Toyoda, Saori ^a   Chen, Li ^b   Kirkner, Gregory J ^b   Wolpin, Brian M ^a   Chan, Andrew T ^b,d   Giovannucci, Edward L ^b,c   Fuchs, Charles S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STATHMIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; BODY MASS INDEX; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; STATHMIN; SURVIVAL RATE;

EID: 68349158956     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.281     Document Type: Article

References (54)

1. Steinmetz MO. Structure and thermodynamics of the tubulin-stathmin interaction. J Struct Biol 2007;158:137-47.
2. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996;84:623-31.
3. Nogales E, Wang HW. Structural intermediates in microtubule assembly and disassembly: how and why? Curr Opin Cell Biol 2006;18:179-84.
4. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002;14:18-24.
5. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004;93:242-50.
6. Johnsen JI, Aurelio ON, Kwaja Z et al. p53-mediated negative regulation of stathmin/Op 1. expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 2000;88:685-91.
7. Baldassarre G, Belletti B, Nicoloso MS et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005;7:51-63.
8. Ji H, Baldwin GS, Burgess AW et al. Epidermal growth factor induces serine phosphorylation of stathmin in a human colon carcinoma cell line (LIM 1215). J Biol Chem 1993;268:13396-405.
9. Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007;104:7564-9.
10. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
11. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
12. Ahn J, Murphy M, Kratowicz S et al. Down-regulation of the stathmin/Op 1. and FKBP 2. genes following p5. induction. Oncogene 1999;18:5954-8.
13. Liu Z, Lu H, Shi H et al. PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res 2005;65:1647-54.
14. Iancu-Rubin C, Atweh GF. p27(Kip1. and stathmin share the stage for the first time. Trends Cell Biol 2005;15:346-8.
15. Friedrich B, Gronberg H, Landstrom M et al. Differentiation-stage specific expression of oncoprotein 1. in human and rat prostatic adenocarcinoma. Prostate 1995;27:102-9.
16. Yuan RH, Jeng YM, Chen HL et al. Stathmin overexpression cooperates with p5. mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209:549-58.
17. Singer S, Ehemann V, Brauckhoff A et al. Protumorigenic overexpression of stathmin/Op1. by gain-of-function mutation in p5. in human hepatocarcinogenesis. Hepatology 2007;46:759-68.
18. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000;83:311-8.
19. Curmi PA, Nogues C, Lachkar S et al. Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 2000;82:142-50.
20. Abal M, Obrador-Hevia A, Janssen KP et al. APC inactivation associates with abnormal mitosis completion and concomitant BUB1B/MAD2L1 upregulation. Gastroenterology 2007;132:2448-58.
21. Golouh R, Cufer T, Sadikov A et al. The prognostic value of Stathmin-1. S100A2. and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008;110:317-26.
22. Ngo TT, Peng T, Liang XJ et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007;99:639-52.
23. Chan AT, Ogino S, Fuchs CS. Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. New Engl J Med 2007;356:2131-42.
24. Rimm EB, Stampfer MJ, Colditz GA et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
25. Ogino S, Nosho K, Meyerhardt JA et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26:5713-20.
26. Ogino S, Kawasaki T, Kirkner GJ et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007;9:305-14.
27. Ogino S, Nosho K, Kirkner GJ et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-8.
28. Ogino S, Kawasaki T, Brahmandam M et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21.
29. Ogino S, Kawasaki T, Kirkner GJ et al. CpG island methylator phenotypelow (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-8.
30. Nosho K, Kawasaki T, Ohnishi M et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-41.
31. Ogino S, Cantor M, Kawasaki T et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-6.
32. Ogino S, kawasaki T, Brahmandam M et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-17.
33. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93.
34. Ogino S, Kawasaki T, Nosho K et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-73.
35. Nosho K, Kawasaki T, Chan AT et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008;53:588-98.
36. Kawasaki T, Nosho K, Ohnishi M et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007;9:569-77.
37. Ogino S, Meyerhardt JA, Cantor M et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6.
38. Ogino S, kawasaki T, Kirkner GJ et al. Down-regulation of p21 (CDKN1A/CIP1. is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006;210:147-54.
39. Ogino S, Brahmandam M, Cantor M et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006;19:59-68.
40. Stang A, Kluttig A. Etiologic insights from surface adjustment of colorectal carcinoma incidences: an analysis of the U.S. SEER data 2000-2004. Am J Gastroenterol 2008;103:2853-61.
41. Sinicrope FA, Rego RL, Foster N et al. Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol 2006;101:2818-25.
42. Leung WK, To KF, Man EP et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 2007;102:1070-6.
43. Li Y, Wang J, Zhu G et al. Detection of parvovirus B1. nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma. Am J Gastroenterol 2007;102:1489-98.
44. Garrity-Park MM, Loft us EV Jr, Bryant SC et al. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2008;103:407-15.
45. Itzkowitz S, Brand R, Jandorf L et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008;103:2862-70.
46. Appelman HD. Con: High-grade dysplasia and villous features should not be part of the routine diagnosis of colorectal adenomas. Am J Gastroenterol 2008;103:1329-31.
47. Yamaji Y, Okamoto M, Yoshida H et al. The effect of body weight reduction on the incidence of colorectal adenoma. Am J Gastroenterol 2008;103:2061-7.
48. Julie C, Tresallet C, Brouquet A et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 2008;103:2825-35. quiz 2836.
49. Toma J, Paszat LF, Gunraj N et al. Rates of new or missed colorectal cancer after bariumenema and their risk factors: a population-based study. Am J Gastroenterol 2008;103:3142-8.
50. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
51. Dignam JJ, Polite BN, Yothers G et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:1647-54.
52. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006;17:145-56.
53. Haydon AM, Macinnis RJ, English DR et al. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 2006;55:62-7.
54. Ikeda S, Sasazuki S, Natsukawa S et al. Screening of 21. single nucleotide polymorphisms in 4. candidate cancer susceptibility genes: a case-control study on gastric and colorectal cancers in the Japanese population. Am J Gastroenterol 2008;103:1476-87.